CANCER LETTERS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2266134, encodeId=9bec2266134df, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：还有朋友是一样的吗，杂志接受了，支付了版面费，然后又被拒稿，而且没有明确原因拒稿，联系方式微：FFFWW101, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a59736045, createdName=ms4000001252060402, createdTime=Thu May 22 10:03:08 CST 2025, time=2025-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256114, encodeId=f72d2256114ff, content=偏重的研究方向：肿瘤 经验分享：求问under review会显示具体送了多少审稿人吗？在决策前一直显示under review吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc889232803, createdName=ms9000001817929142, createdTime=Fri Mar 14 18:55:18 CST 2025, time=2025-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246357, encodeId=3a94224635ede, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：临床肿瘤 经验分享：2024.4.9：submitted; 2024.10.6: Require reviewers completed; 2024.11.07:Major revision; 2024.12.16:Revision Submitted to Journal; 2024.12.17:with editor; 2024.12.18:under review; 2024.12.27:Required Reviews Completed; 2024.12.30:Decision in process; 2025.01.01:Accept; 2025.01.02:proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134c2294591, createdName=121f2f52m05(暂无昵称), createdTime=Fri Jan 03 14:11:31 CST 2025, time=2025-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242784, encodeId=99fe2242e845e, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投了1篇，前后修回了6轮，太不容易了，终于接收了，明年应该就10分以上了，希望能再接再厉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/09/3c521de7fe7837936c39b47e71d5b9b4.jpg, createdBy=a37f2090445, createdName=dsaef, createdTime=Mon Dec 16 08:20:07 CST 2024, time=2024-12-16, status=1, ipAttribution=俄克拉何马), GetPortalCommentsPageByObjectIdResponse(id=2232848, encodeId=751422328484e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;耐药机制 经验分享：05.22 Submitted to Journal 05.22 With editor 05.24 Under review 06.14 Required reviews completed 06.18 Major revision 两个审稿人一审给了一个月时间。第一个大小20多个意见，很细节都好解决。第二个一个意见，要求换个动物模型验证。为了满足第二个审稿人的意见修改时间延长了两个月。 09.17 Revision Submitted to Journal 09.20 Under review 09.27 Required reviews completed 10.01 Minor revision 二审给了7天时间。第一个审稿人认为几乎适合发表，基于revision note的内容又提了三个意见，加点文字说明和补充数据。第二个审稿人认为可以接收发表。 10.07 Revision Submitted to Journal 10.08 With Editor 10.13 Under review 10.15 Required reviews completed 三审的节奏明显慢了，不知道啥时候给信，焦虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779a5593142, createdName=gkswnd, createdTime=Thu Oct 24 12:21:27 CST 2024, time=2024-10-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223722, encodeId=e4d62223e22c0, content=接accept，接accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d9e8506295, createdName=ms4000000067455992, createdTime=Mon Sep 02 18:01:03 CST 2024, time=2024-09-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间 05/05/2024 投稿 05/07/2024 With editor 05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2229206, encodeId=761f222920678, content=我提交后登录通讯作者账号，看不到我提交的文章是什么情况呀？求求救救孩子吧~~ Submissions Waiting for Author's Approval (0), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf9484434, createdName=ms9000001717949106, createdTime=Fri Oct 04 15:19:54 CST 2024, time=2024-10-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2171958, encodeId=1f2321e19589a, content=09/10/2023 投稿 09/20/2023 under review 11/13/2023 2个审稿意见大修，编辑果断拒稿，毕业季投这个真的伤不起，本来不想曝光这个沙雕杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651e8489728, createdName=ms2000000020645198, createdTime=Wed Nov 29 22:04:44 CST 2023, time=2023-11-29, status=1, ipAttribution=北京)]

2025-05-22 ms4000001252060402 来自广东省

审稿速度:2.0 | 投稿命中率:95.0
经验分享：还有朋友是一样的吗，杂志接受了，支付了版面费，然后又被拒稿，而且没有明确原因拒稿，联系方式微：FFFWW101

9 0

[GetPortalCommentsPageByObjectIdResponse(id=2266134, encodeId=9bec2266134df, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：还有朋友是一样的吗，杂志接受了，支付了版面费，然后又被拒稿，而且没有明确原因拒稿，联系方式微：FFFWW101, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a59736045, createdName=ms4000001252060402, createdTime=Thu May 22 10:03:08 CST 2025, time=2025-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256114, encodeId=f72d2256114ff, content=偏重的研究方向：肿瘤 经验分享：求问under review会显示具体送了多少审稿人吗？在决策前一直显示under review吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc889232803, createdName=ms9000001817929142, createdTime=Fri Mar 14 18:55:18 CST 2025, time=2025-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246357, encodeId=3a94224635ede, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：临床肿瘤 经验分享：2024.4.9：submitted; 2024.10.6: Require reviewers completed; 2024.11.07:Major revision; 2024.12.16:Revision Submitted to Journal; 2024.12.17:with editor; 2024.12.18:under review; 2024.12.27:Required Reviews Completed; 2024.12.30:Decision in process; 2025.01.01:Accept; 2025.01.02:proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134c2294591, createdName=121f2f52m05(暂无昵称), createdTime=Fri Jan 03 14:11:31 CST 2025, time=2025-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242784, encodeId=99fe2242e845e, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投了1篇，前后修回了6轮，太不容易了，终于接收了，明年应该就10分以上了，希望能再接再厉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/09/3c521de7fe7837936c39b47e71d5b9b4.jpg, createdBy=a37f2090445, createdName=dsaef, createdTime=Mon Dec 16 08:20:07 CST 2024, time=2024-12-16, status=1, ipAttribution=俄克拉何马), GetPortalCommentsPageByObjectIdResponse(id=2232848, encodeId=751422328484e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;耐药机制 经验分享：05.22 Submitted to Journal 05.22 With editor 05.24 Under review 06.14 Required reviews completed 06.18 Major revision 两个审稿人一审给了一个月时间。第一个大小20多个意见，很细节都好解决。第二个一个意见，要求换个动物模型验证。为了满足第二个审稿人的意见修改时间延长了两个月。 09.17 Revision Submitted to Journal 09.20 Under review 09.27 Required reviews completed 10.01 Minor revision 二审给了7天时间。第一个审稿人认为几乎适合发表，基于revision note的内容又提了三个意见，加点文字说明和补充数据。第二个审稿人认为可以接收发表。 10.07 Revision Submitted to Journal 10.08 With Editor 10.13 Under review 10.15 Required reviews completed 三审的节奏明显慢了，不知道啥时候给信，焦虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779a5593142, createdName=gkswnd, createdTime=Thu Oct 24 12:21:27 CST 2024, time=2024-10-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223722, encodeId=e4d62223e22c0, content=接accept，接accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d9e8506295, createdName=ms4000000067455992, createdTime=Mon Sep 02 18:01:03 CST 2024, time=2024-09-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间 05/05/2024 投稿 05/07/2024 With editor 05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2229206, encodeId=761f222920678, content=我提交后登录通讯作者账号，看不到我提交的文章是什么情况呀？求求救救孩子吧~~ Submissions Waiting for Author's Approval (0), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf9484434, createdName=ms9000001717949106, createdTime=Fri Oct 04 15:19:54 CST 2024, time=2024-10-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2171958, encodeId=1f2321e19589a, content=09/10/2023 投稿 09/20/2023 under review 11/13/2023 2个审稿意见大修，编辑果断拒稿，毕业季投这个真的伤不起，本来不想曝光这个沙雕杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651e8489728, createdName=ms2000000020645198, createdTime=Wed Nov 29 22:04:44 CST 2023, time=2023-11-29, status=1, ipAttribution=北京)]

2025-03-14 ms9000001817929142 来自北京

偏重的研究方向：肿瘤
经验分享：求问under review会显示具体送了多少审稿人吗？在决策前一直显示under review吗？

20 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2266134, encodeId=9bec2266134df, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：还有朋友是一样的吗，杂志接受了，支付了版面费，然后又被拒稿，而且没有明确原因拒稿，联系方式微：FFFWW101, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a59736045, createdName=ms4000001252060402, createdTime=Thu May 22 10:03:08 CST 2025, time=2025-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256114, encodeId=f72d2256114ff, content=偏重的研究方向：肿瘤 经验分享：求问under review会显示具体送了多少审稿人吗？在决策前一直显示under review吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc889232803, createdName=ms9000001817929142, createdTime=Fri Mar 14 18:55:18 CST 2025, time=2025-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246357, encodeId=3a94224635ede, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：临床肿瘤 经验分享：2024.4.9：submitted; 2024.10.6: Require reviewers completed; 2024.11.07:Major revision; 2024.12.16:Revision Submitted to Journal; 2024.12.17:with editor; 2024.12.18:under review; 2024.12.27:Required Reviews Completed; 2024.12.30:Decision in process; 2025.01.01:Accept; 2025.01.02:proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134c2294591, createdName=121f2f52m05(暂无昵称), createdTime=Fri Jan 03 14:11:31 CST 2025, time=2025-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242784, encodeId=99fe2242e845e, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投了1篇，前后修回了6轮，太不容易了，终于接收了，明年应该就10分以上了，希望能再接再厉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/09/3c521de7fe7837936c39b47e71d5b9b4.jpg, createdBy=a37f2090445, createdName=dsaef, createdTime=Mon Dec 16 08:20:07 CST 2024, time=2024-12-16, status=1, ipAttribution=俄克拉何马), GetPortalCommentsPageByObjectIdResponse(id=2232848, encodeId=751422328484e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;耐药机制 经验分享：05.22 Submitted to Journal 05.22 With editor 05.24 Under review 06.14 Required reviews completed 06.18 Major revision 两个审稿人一审给了一个月时间。第一个大小20多个意见，很细节都好解决。第二个一个意见，要求换个动物模型验证。为了满足第二个审稿人的意见修改时间延长了两个月。 09.17 Revision Submitted to Journal 09.20 Under review 09.27 Required reviews completed 10.01 Minor revision 二审给了7天时间。第一个审稿人认为几乎适合发表，基于revision note的内容又提了三个意见，加点文字说明和补充数据。第二个审稿人认为可以接收发表。 10.07 Revision Submitted to Journal 10.08 With Editor 10.13 Under review 10.15 Required reviews completed 三审的节奏明显慢了，不知道啥时候给信，焦虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779a5593142, createdName=gkswnd, createdTime=Thu Oct 24 12:21:27 CST 2024, time=2024-10-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223722, encodeId=e4d62223e22c0, content=接accept，接accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d9e8506295, createdName=ms4000000067455992, createdTime=Mon Sep 02 18:01:03 CST 2024, time=2024-09-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间 05/05/2024 投稿 05/07/2024 With editor 05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2229206, encodeId=761f222920678, content=我提交后登录通讯作者账号，看不到我提交的文章是什么情况呀？求求救救孩子吧~~ Submissions Waiting for Author's Approval (0), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf9484434, createdName=ms9000001717949106, createdTime=Fri Oct 04 15:19:54 CST 2024, time=2024-10-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2171958, encodeId=1f2321e19589a, content=09/10/2023 投稿 09/20/2023 under review 11/13/2023 2个审稿意见大修，编辑果断拒稿，毕业季投这个真的伤不起，本来不想曝光这个沙雕杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651e8489728, createdName=ms2000000020645198, createdTime=Wed Nov 29 22:04:44 CST 2023, time=2023-11-29, status=1, ipAttribution=北京)]

2025-01-03 121f2f52m05(暂无昵称) 来自上海

审稿速度:12.0 | 投稿命中率:50.0
偏重的研究方向：临床肿瘤
经验分享：2024.4.9：submitted;
2024.10.6: Require reviewers completed;
2024.11.07:Major revision;
2024.12.16:Revision Submitted to Journal;
2024.12.17:with editor;
2024.12.18:under review;
2024.12.27:Required Reviews Completed;
2024.12.30:Decision in process;
2025.01.01:Accept;
2025.01.02:proof

48 0

[GetPortalCommentsPageByObjectIdResponse(id=2266134, encodeId=9bec2266134df, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：还有朋友是一样的吗，杂志接受了，支付了版面费，然后又被拒稿，而且没有明确原因拒稿，联系方式微：FFFWW101, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a59736045, createdName=ms4000001252060402, createdTime=Thu May 22 10:03:08 CST 2025, time=2025-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256114, encodeId=f72d2256114ff, content=偏重的研究方向：肿瘤 经验分享：求问under review会显示具体送了多少审稿人吗？在决策前一直显示under review吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc889232803, createdName=ms9000001817929142, createdTime=Fri Mar 14 18:55:18 CST 2025, time=2025-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246357, encodeId=3a94224635ede, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：临床肿瘤 经验分享：2024.4.9：submitted; 2024.10.6: Require reviewers completed; 2024.11.07:Major revision; 2024.12.16:Revision Submitted to Journal; 2024.12.17:with editor; 2024.12.18:under review; 2024.12.27:Required Reviews Completed; 2024.12.30:Decision in process; 2025.01.01:Accept; 2025.01.02:proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134c2294591, createdName=121f2f52m05(暂无昵称), createdTime=Fri Jan 03 14:11:31 CST 2025, time=2025-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242784, encodeId=99fe2242e845e, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投了1篇，前后修回了6轮，太不容易了，终于接收了，明年应该就10分以上了，希望能再接再厉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/09/3c521de7fe7837936c39b47e71d5b9b4.jpg, createdBy=a37f2090445, createdName=dsaef, createdTime=Mon Dec 16 08:20:07 CST 2024, time=2024-12-16, status=1, ipAttribution=俄克拉何马), GetPortalCommentsPageByObjectIdResponse(id=2232848, encodeId=751422328484e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;耐药机制 经验分享：05.22 Submitted to Journal 05.22 With editor 05.24 Under review 06.14 Required reviews completed 06.18 Major revision 两个审稿人一审给了一个月时间。第一个大小20多个意见，很细节都好解决。第二个一个意见，要求换个动物模型验证。为了满足第二个审稿人的意见修改时间延长了两个月。 09.17 Revision Submitted to Journal 09.20 Under review 09.27 Required reviews completed 10.01 Minor revision 二审给了7天时间。第一个审稿人认为几乎适合发表，基于revision note的内容又提了三个意见，加点文字说明和补充数据。第二个审稿人认为可以接收发表。 10.07 Revision Submitted to Journal 10.08 With Editor 10.13 Under review 10.15 Required reviews completed 三审的节奏明显慢了，不知道啥时候给信，焦虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779a5593142, createdName=gkswnd, createdTime=Thu Oct 24 12:21:27 CST 2024, time=2024-10-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223722, encodeId=e4d62223e22c0, content=接accept，接accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d9e8506295, createdName=ms4000000067455992, createdTime=Mon Sep 02 18:01:03 CST 2024, time=2024-09-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间 05/05/2024 投稿 05/07/2024 With editor 05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2229206, encodeId=761f222920678, content=我提交后登录通讯作者账号，看不到我提交的文章是什么情况呀？求求救救孩子吧~~ Submissions Waiting for Author's Approval (0), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf9484434, createdName=ms9000001717949106, createdTime=Fri Oct 04 15:19:54 CST 2024, time=2024-10-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2171958, encodeId=1f2321e19589a, content=09/10/2023 投稿 09/20/2023 under review 11/13/2023 2个审稿意见大修，编辑果断拒稿，毕业季投这个真的伤不起，本来不想曝光这个沙雕杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651e8489728, createdName=ms2000000020645198, createdTime=Wed Nov 29 22:04:44 CST 2023, time=2023-11-29, status=1, ipAttribution=北京)]

2024-12-16 dsaef 来自俄克拉何马

审稿速度:6.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤
经验分享：投了1篇，前后修回了6轮，太不容易了，终于接收了，明年应该就10分以上了，希望能再接再厉！

40 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2266134, encodeId=9bec2266134df, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：还有朋友是一样的吗，杂志接受了，支付了版面费，然后又被拒稿，而且没有明确原因拒稿，联系方式微：FFFWW101, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a59736045, createdName=ms4000001252060402, createdTime=Thu May 22 10:03:08 CST 2025, time=2025-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256114, encodeId=f72d2256114ff, content=偏重的研究方向：肿瘤 经验分享：求问under review会显示具体送了多少审稿人吗？在决策前一直显示under review吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc889232803, createdName=ms9000001817929142, createdTime=Fri Mar 14 18:55:18 CST 2025, time=2025-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246357, encodeId=3a94224635ede, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：临床肿瘤 经验分享：2024.4.9：submitted; 2024.10.6: Require reviewers completed; 2024.11.07:Major revision; 2024.12.16:Revision Submitted to Journal; 2024.12.17:with editor; 2024.12.18:under review; 2024.12.27:Required Reviews Completed; 2024.12.30:Decision in process; 2025.01.01:Accept; 2025.01.02:proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134c2294591, createdName=121f2f52m05(暂无昵称), createdTime=Fri Jan 03 14:11:31 CST 2025, time=2025-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242784, encodeId=99fe2242e845e, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投了1篇，前后修回了6轮，太不容易了，终于接收了，明年应该就10分以上了，希望能再接再厉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/09/3c521de7fe7837936c39b47e71d5b9b4.jpg, createdBy=a37f2090445, createdName=dsaef, createdTime=Mon Dec 16 08:20:07 CST 2024, time=2024-12-16, status=1, ipAttribution=俄克拉何马), GetPortalCommentsPageByObjectIdResponse(id=2232848, encodeId=751422328484e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;耐药机制 经验分享：05.22 Submitted to Journal 05.22 With editor 05.24 Under review 06.14 Required reviews completed 06.18 Major revision 两个审稿人一审给了一个月时间。第一个大小20多个意见，很细节都好解决。第二个一个意见，要求换个动物模型验证。为了满足第二个审稿人的意见修改时间延长了两个月。 09.17 Revision Submitted to Journal 09.20 Under review 09.27 Required reviews completed 10.01 Minor revision 二审给了7天时间。第一个审稿人认为几乎适合发表，基于revision note的内容又提了三个意见，加点文字说明和补充数据。第二个审稿人认为可以接收发表。 10.07 Revision Submitted to Journal 10.08 With Editor 10.13 Under review 10.15 Required reviews completed 三审的节奏明显慢了，不知道啥时候给信，焦虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779a5593142, createdName=gkswnd, createdTime=Thu Oct 24 12:21:27 CST 2024, time=2024-10-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223722, encodeId=e4d62223e22c0, content=接accept，接accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d9e8506295, createdName=ms4000000067455992, createdTime=Mon Sep 02 18:01:03 CST 2024, time=2024-09-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间 05/05/2024 投稿 05/07/2024 With editor 05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2229206, encodeId=761f222920678, content=我提交后登录通讯作者账号，看不到我提交的文章是什么情况呀？求求救救孩子吧~~ Submissions Waiting for Author's Approval (0), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf9484434, createdName=ms9000001717949106, createdTime=Fri Oct 04 15:19:54 CST 2024, time=2024-10-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2171958, encodeId=1f2321e19589a, content=09/10/2023 投稿 09/20/2023 under review 11/13/2023 2个审稿意见大修，编辑果断拒稿，毕业季投这个真的伤不起，本来不想曝光这个沙雕杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651e8489728, createdName=ms2000000020645198, createdTime=Wed Nov 29 22:04:44 CST 2023, time=2023-11-29, status=1, ipAttribution=北京)]

2024-10-24 gkswnd 来自广东省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;耐药机制
经验分享：05.22 Submitted to Journal
05.22 With editor
05.24 Under review
06.14 Required reviews completed
06.18 Major revision
两个审稿人一审给了一个月时间。第一个大小20多个意见，很细节都好解决。第二个一个意见，要求换个动物模型验证。为了满足第二个审稿人的意见修改时间延长了两个月。
09.17 Revision Submitted to Journal
09.20 Under review
09.27 Required reviews completed
10.01 Minor revision
二审给了7天时间。第一个审稿人认为几乎适合发表，基于revision note的内容又提了三个意见，加点文字说明和补充数据。第二个审稿人认为可以接收发表。
10.07 Revision Submitted to Journal
10.08 With Editor
10.13 Under review
10.15 Required reviews completed
三审的节奏明显慢了，不知道啥时候给信，焦虑。

73 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2266134, encodeId=9bec2266134df, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：还有朋友是一样的吗，杂志接受了，支付了版面费，然后又被拒稿，而且没有明确原因拒稿，联系方式微：FFFWW101, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a59736045, createdName=ms4000001252060402, createdTime=Thu May 22 10:03:08 CST 2025, time=2025-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256114, encodeId=f72d2256114ff, content=偏重的研究方向：肿瘤 经验分享：求问under review会显示具体送了多少审稿人吗？在决策前一直显示under review吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc889232803, createdName=ms9000001817929142, createdTime=Fri Mar 14 18:55:18 CST 2025, time=2025-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246357, encodeId=3a94224635ede, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：临床肿瘤 经验分享：2024.4.9：submitted; 2024.10.6: Require reviewers completed; 2024.11.07:Major revision; 2024.12.16:Revision Submitted to Journal; 2024.12.17:with editor; 2024.12.18:under review; 2024.12.27:Required Reviews Completed; 2024.12.30:Decision in process; 2025.01.01:Accept; 2025.01.02:proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134c2294591, createdName=121f2f52m05(暂无昵称), createdTime=Fri Jan 03 14:11:31 CST 2025, time=2025-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242784, encodeId=99fe2242e845e, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投了1篇，前后修回了6轮，太不容易了，终于接收了，明年应该就10分以上了，希望能再接再厉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/09/3c521de7fe7837936c39b47e71d5b9b4.jpg, createdBy=a37f2090445, createdName=dsaef, createdTime=Mon Dec 16 08:20:07 CST 2024, time=2024-12-16, status=1, ipAttribution=俄克拉何马), GetPortalCommentsPageByObjectIdResponse(id=2232848, encodeId=751422328484e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;耐药机制 经验分享：05.22 Submitted to Journal 05.22 With editor 05.24 Under review 06.14 Required reviews completed 06.18 Major revision 两个审稿人一审给了一个月时间。第一个大小20多个意见，很细节都好解决。第二个一个意见，要求换个动物模型验证。为了满足第二个审稿人的意见修改时间延长了两个月。 09.17 Revision Submitted to Journal 09.20 Under review 09.27 Required reviews completed 10.01 Minor revision 二审给了7天时间。第一个审稿人认为几乎适合发表，基于revision note的内容又提了三个意见，加点文字说明和补充数据。第二个审稿人认为可以接收发表。 10.07 Revision Submitted to Journal 10.08 With Editor 10.13 Under review 10.15 Required reviews completed 三审的节奏明显慢了，不知道啥时候给信，焦虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779a5593142, createdName=gkswnd, createdTime=Thu Oct 24 12:21:27 CST 2024, time=2024-10-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223722, encodeId=e4d62223e22c0, content=接accept，接accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d9e8506295, createdName=ms4000000067455992, createdTime=Mon Sep 02 18:01:03 CST 2024, time=2024-09-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间 05/05/2024 投稿 05/07/2024 With editor 05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2229206, encodeId=761f222920678, content=我提交后登录通讯作者账号，看不到我提交的文章是什么情况呀？求求救救孩子吧~~ Submissions Waiting for Author's Approval (0), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf9484434, createdName=ms9000001717949106, createdTime=Fri Oct 04 15:19:54 CST 2024, time=2024-10-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2171958, encodeId=1f2321e19589a, content=09/10/2023 投稿 09/20/2023 under review 11/13/2023 2个审稿意见大修，编辑果断拒稿，毕业季投这个真的伤不起，本来不想曝光这个沙雕杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651e8489728, createdName=ms2000000020645198, createdTime=Wed Nov 29 22:04:44 CST 2023, time=2023-11-29, status=1, ipAttribution=北京)]

2024-09-02 ms4000000067455992 来自重庆

接accept，接accept

93 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2266134, encodeId=9bec2266134df, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：还有朋友是一样的吗，杂志接受了，支付了版面费，然后又被拒稿，而且没有明确原因拒稿，联系方式微：FFFWW101, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a59736045, createdName=ms4000001252060402, createdTime=Thu May 22 10:03:08 CST 2025, time=2025-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256114, encodeId=f72d2256114ff, content=偏重的研究方向：肿瘤 经验分享：求问under review会显示具体送了多少审稿人吗？在决策前一直显示under review吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc889232803, createdName=ms9000001817929142, createdTime=Fri Mar 14 18:55:18 CST 2025, time=2025-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246357, encodeId=3a94224635ede, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：临床肿瘤 经验分享：2024.4.9：submitted; 2024.10.6: Require reviewers completed; 2024.11.07:Major revision; 2024.12.16:Revision Submitted to Journal; 2024.12.17:with editor; 2024.12.18:under review; 2024.12.27:Required Reviews Completed; 2024.12.30:Decision in process; 2025.01.01:Accept; 2025.01.02:proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134c2294591, createdName=121f2f52m05(暂无昵称), createdTime=Fri Jan 03 14:11:31 CST 2025, time=2025-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242784, encodeId=99fe2242e845e, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投了1篇，前后修回了6轮，太不容易了，终于接收了，明年应该就10分以上了，希望能再接再厉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/09/3c521de7fe7837936c39b47e71d5b9b4.jpg, createdBy=a37f2090445, createdName=dsaef, createdTime=Mon Dec 16 08:20:07 CST 2024, time=2024-12-16, status=1, ipAttribution=俄克拉何马), GetPortalCommentsPageByObjectIdResponse(id=2232848, encodeId=751422328484e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;耐药机制 经验分享：05.22 Submitted to Journal 05.22 With editor 05.24 Under review 06.14 Required reviews completed 06.18 Major revision 两个审稿人一审给了一个月时间。第一个大小20多个意见，很细节都好解决。第二个一个意见，要求换个动物模型验证。为了满足第二个审稿人的意见修改时间延长了两个月。 09.17 Revision Submitted to Journal 09.20 Under review 09.27 Required reviews completed 10.01 Minor revision 二审给了7天时间。第一个审稿人认为几乎适合发表，基于revision note的内容又提了三个意见，加点文字说明和补充数据。第二个审稿人认为可以接收发表。 10.07 Revision Submitted to Journal 10.08 With Editor 10.13 Under review 10.15 Required reviews completed 三审的节奏明显慢了，不知道啥时候给信，焦虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779a5593142, createdName=gkswnd, createdTime=Thu Oct 24 12:21:27 CST 2024, time=2024-10-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223722, encodeId=e4d62223e22c0, content=接accept，接accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d9e8506295, createdName=ms4000000067455992, createdTime=Mon Sep 02 18:01:03 CST 2024, time=2024-09-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间 05/05/2024 投稿 05/07/2024 With editor 05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2229206, encodeId=761f222920678, content=我提交后登录通讯作者账号，看不到我提交的文章是什么情况呀？求求救救孩子吧~~ Submissions Waiting for Author's Approval (0), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf9484434, createdName=ms9000001717949106, createdTime=Fri Oct 04 15:19:54 CST 2024, time=2024-10-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2171958, encodeId=1f2321e19589a, content=09/10/2023 投稿 09/20/2023 under review 11/13/2023 2个审稿意见大修，编辑果断拒稿，毕业季投这个真的伤不起，本来不想曝光这个沙雕杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651e8489728, createdName=ms2000000020645198, createdTime=Wed Nov 29 22:04:44 CST 2023, time=2023-11-29, status=1, ipAttribution=北京)]

2024-05-09 ms3000000772221561 来自上海

第二次投cancer letters，记录时间
05/05/2024 投稿
05/07/2024 With editor
05/08/2024 Under Review

127 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2266134, encodeId=9bec2266134df, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：还有朋友是一样的吗，杂志接受了，支付了版面费，然后又被拒稿，而且没有明确原因拒稿，联系方式微：FFFWW101, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a59736045, createdName=ms4000001252060402, createdTime=Thu May 22 10:03:08 CST 2025, time=2025-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256114, encodeId=f72d2256114ff, content=偏重的研究方向：肿瘤 经验分享：求问under review会显示具体送了多少审稿人吗？在决策前一直显示under review吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc889232803, createdName=ms9000001817929142, createdTime=Fri Mar 14 18:55:18 CST 2025, time=2025-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246357, encodeId=3a94224635ede, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：临床肿瘤 经验分享：2024.4.9：submitted; 2024.10.6: Require reviewers completed; 2024.11.07:Major revision; 2024.12.16:Revision Submitted to Journal; 2024.12.17:with editor; 2024.12.18:under review; 2024.12.27:Required Reviews Completed; 2024.12.30:Decision in process; 2025.01.01:Accept; 2025.01.02:proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134c2294591, createdName=121f2f52m05(暂无昵称), createdTime=Fri Jan 03 14:11:31 CST 2025, time=2025-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242784, encodeId=99fe2242e845e, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投了1篇，前后修回了6轮，太不容易了，终于接收了，明年应该就10分以上了，希望能再接再厉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/09/3c521de7fe7837936c39b47e71d5b9b4.jpg, createdBy=a37f2090445, createdName=dsaef, createdTime=Mon Dec 16 08:20:07 CST 2024, time=2024-12-16, status=1, ipAttribution=俄克拉何马), GetPortalCommentsPageByObjectIdResponse(id=2232848, encodeId=751422328484e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;耐药机制 经验分享：05.22 Submitted to Journal 05.22 With editor 05.24 Under review 06.14 Required reviews completed 06.18 Major revision 两个审稿人一审给了一个月时间。第一个大小20多个意见，很细节都好解决。第二个一个意见，要求换个动物模型验证。为了满足第二个审稿人的意见修改时间延长了两个月。 09.17 Revision Submitted to Journal 09.20 Under review 09.27 Required reviews completed 10.01 Minor revision 二审给了7天时间。第一个审稿人认为几乎适合发表，基于revision note的内容又提了三个意见，加点文字说明和补充数据。第二个审稿人认为可以接收发表。 10.07 Revision Submitted to Journal 10.08 With Editor 10.13 Under review 10.15 Required reviews completed 三审的节奏明显慢了，不知道啥时候给信，焦虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779a5593142, createdName=gkswnd, createdTime=Thu Oct 24 12:21:27 CST 2024, time=2024-10-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223722, encodeId=e4d62223e22c0, content=接accept，接accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d9e8506295, createdName=ms4000000067455992, createdTime=Mon Sep 02 18:01:03 CST 2024, time=2024-09-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间 05/05/2024 投稿 05/07/2024 With editor 05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2229206, encodeId=761f222920678, content=我提交后登录通讯作者账号，看不到我提交的文章是什么情况呀？求求救救孩子吧~~ Submissions Waiting for Author's Approval (0), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf9484434, createdName=ms9000001717949106, createdTime=Fri Oct 04 15:19:54 CST 2024, time=2024-10-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2171958, encodeId=1f2321e19589a, content=09/10/2023 投稿 09/20/2023 under review 11/13/2023 2个审稿意见大修，编辑果断拒稿，毕业季投这个真的伤不起，本来不想曝光这个沙雕杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651e8489728, createdName=ms2000000020645198, createdTime=Wed Nov 29 22:04:44 CST 2023, time=2023-11-29, status=1, ipAttribution=北京)]

2024-10-04 ms9000001717949106 来自北京

我提交后登录通讯作者账号，看不到我提交的文章是什么情况呀？求求救救孩子吧~~
Submissions Waiting for Author's Approval (0)

63 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2266134, encodeId=9bec2266134df, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：还有朋友是一样的吗，杂志接受了，支付了版面费，然后又被拒稿，而且没有明确原因拒稿，联系方式微：FFFWW101, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a59736045, createdName=ms4000001252060402, createdTime=Thu May 22 10:03:08 CST 2025, time=2025-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256114, encodeId=f72d2256114ff, content=偏重的研究方向：肿瘤 经验分享：求问under review会显示具体送了多少审稿人吗？在决策前一直显示under review吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc889232803, createdName=ms9000001817929142, createdTime=Fri Mar 14 18:55:18 CST 2025, time=2025-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246357, encodeId=3a94224635ede, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：临床肿瘤 经验分享：2024.4.9：submitted; 2024.10.6: Require reviewers completed; 2024.11.07:Major revision; 2024.12.16:Revision Submitted to Journal; 2024.12.17:with editor; 2024.12.18:under review; 2024.12.27:Required Reviews Completed; 2024.12.30:Decision in process; 2025.01.01:Accept; 2025.01.02:proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134c2294591, createdName=121f2f52m05(暂无昵称), createdTime=Fri Jan 03 14:11:31 CST 2025, time=2025-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242784, encodeId=99fe2242e845e, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投了1篇，前后修回了6轮，太不容易了，终于接收了，明年应该就10分以上了，希望能再接再厉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/09/3c521de7fe7837936c39b47e71d5b9b4.jpg, createdBy=a37f2090445, createdName=dsaef, createdTime=Mon Dec 16 08:20:07 CST 2024, time=2024-12-16, status=1, ipAttribution=俄克拉何马), GetPortalCommentsPageByObjectIdResponse(id=2232848, encodeId=751422328484e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;耐药机制 经验分享：05.22 Submitted to Journal 05.22 With editor 05.24 Under review 06.14 Required reviews completed 06.18 Major revision 两个审稿人一审给了一个月时间。第一个大小20多个意见，很细节都好解决。第二个一个意见，要求换个动物模型验证。为了满足第二个审稿人的意见修改时间延长了两个月。 09.17 Revision Submitted to Journal 09.20 Under review 09.27 Required reviews completed 10.01 Minor revision 二审给了7天时间。第一个审稿人认为几乎适合发表，基于revision note的内容又提了三个意见，加点文字说明和补充数据。第二个审稿人认为可以接收发表。 10.07 Revision Submitted to Journal 10.08 With Editor 10.13 Under review 10.15 Required reviews completed 三审的节奏明显慢了，不知道啥时候给信，焦虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779a5593142, createdName=gkswnd, createdTime=Thu Oct 24 12:21:27 CST 2024, time=2024-10-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223722, encodeId=e4d62223e22c0, content=接accept，接accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d9e8506295, createdName=ms4000000067455992, createdTime=Mon Sep 02 18:01:03 CST 2024, time=2024-09-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间 05/05/2024 投稿 05/07/2024 With editor 05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2229206, encodeId=761f222920678, content=我提交后登录通讯作者账号，看不到我提交的文章是什么情况呀？求求救救孩子吧~~ Submissions Waiting for Author's Approval (0), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf9484434, createdName=ms9000001717949106, createdTime=Fri Oct 04 15:19:54 CST 2024, time=2024-10-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2171958, encodeId=1f2321e19589a, content=09/10/2023 投稿 09/20/2023 under review 11/13/2023 2个审稿意见大修，编辑果断拒稿，毕业季投这个真的伤不起，本来不想曝光这个沙雕杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651e8489728, createdName=ms2000000020645198, createdTime=Wed Nov 29 22:04:44 CST 2023, time=2023-11-29, status=1, ipAttribution=北京)]

2023-08-15 biocell160 来自贵州省

8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！

158 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2266134, encodeId=9bec2266134df, content=审稿速度:2.0 | 投稿命中率:95.0 经验分享：还有朋友是一样的吗，杂志接受了，支付了版面费，然后又被拒稿，而且没有明确原因拒稿，联系方式微：FFFWW101, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72a59736045, createdName=ms4000001252060402, createdTime=Thu May 22 10:03:08 CST 2025, time=2025-05-22, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256114, encodeId=f72d2256114ff, content=偏重的研究方向：肿瘤 经验分享：求问under review会显示具体送了多少审稿人吗？在决策前一直显示under review吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc889232803, createdName=ms9000001817929142, createdTime=Fri Mar 14 18:55:18 CST 2025, time=2025-03-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2246357, encodeId=3a94224635ede, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：临床肿瘤 经验分享：2024.4.9：submitted; 2024.10.6: Require reviewers completed; 2024.11.07:Major revision; 2024.12.16:Revision Submitted to Journal; 2024.12.17:with editor; 2024.12.18:under review; 2024.12.27:Required Reviews Completed; 2024.12.30:Decision in process; 2025.01.01:Accept; 2025.01.02:proof, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=134c2294591, createdName=121f2f52m05(暂无昵称), createdTime=Fri Jan 03 14:11:31 CST 2025, time=2025-01-03, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2242784, encodeId=99fe2242e845e, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤 经验分享：投了1篇，前后修回了6轮，太不容易了，终于接收了，明年应该就10分以上了，希望能再接再厉！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/09/3c521de7fe7837936c39b47e71d5b9b4.jpg, createdBy=a37f2090445, createdName=dsaef, createdTime=Mon Dec 16 08:20:07 CST 2024, time=2024-12-16, status=1, ipAttribution=俄克拉何马), GetPortalCommentsPageByObjectIdResponse(id=2232848, encodeId=751422328484e, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;耐药机制 经验分享：05.22 Submitted to Journal 05.22 With editor 05.24 Under review 06.14 Required reviews completed 06.18 Major revision 两个审稿人一审给了一个月时间。第一个大小20多个意见，很细节都好解决。第二个一个意见，要求换个动物模型验证。为了满足第二个审稿人的意见修改时间延长了两个月。 09.17 Revision Submitted to Journal 09.20 Under review 09.27 Required reviews completed 10.01 Minor revision 二审给了7天时间。第一个审稿人认为几乎适合发表，基于revision note的内容又提了三个意见，加点文字说明和补充数据。第二个审稿人认为可以接收发表。 10.07 Revision Submitted to Journal 10.08 With Editor 10.13 Under review 10.15 Required reviews completed 三审的节奏明显慢了，不知道啥时候给信，焦虑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=779a5593142, createdName=gkswnd, createdTime=Thu Oct 24 12:21:27 CST 2024, time=2024-10-24, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2223722, encodeId=e4d62223e22c0, content=接accept，接accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d9e8506295, createdName=ms4000000067455992, createdTime=Mon Sep 02 18:01:03 CST 2024, time=2024-09-02, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间 05/05/2024 投稿 05/07/2024 With editor 05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2229206, encodeId=761f222920678, content=我提交后登录通讯作者账号，看不到我提交的文章是什么情况呀？求求救救孩子吧~~ Submissions Waiting for Author's Approval (0), beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adbf9484434, createdName=ms9000001717949106, createdTime=Fri Oct 04 15:19:54 CST 2024, time=2024-10-04, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2171958, encodeId=1f2321e19589a, content=09/10/2023 投稿 09/20/2023 under review 11/13/2023 2个审稿意见大修，编辑果断拒稿，毕业季投这个真的伤不起，本来不想曝光这个沙雕杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=651e8489728, createdName=ms2000000020645198, createdTime=Wed Nov 29 22:04:44 CST 2023, time=2023-11-29, status=1, ipAttribution=北京)]

2023-11-29 ms2000000020645198 来自北京

09/10/2023 投稿
09/20/2023 under review
11/13/2023 2个审稿意见大修，编辑果断拒稿，毕业季投这个真的伤不起，本来不想曝光这个沙雕杂志

148 4

展开4条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务